Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07668388 · ClinicalTrials.gov registry record · Phase 2
A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes
A Phase 2 study, sponsored by Novo Nordisk A/S.
- Not yet
- Registry status
- Phase 2
- Development phase
- 300
- Enrollment target
NCT07668388 is a Phase 2 study that has not yet begun recruiting, run by Novo Nordisk A/S. The registered enrollment target is 300 participants.
The verdict
NCT07668388, a Phase 2 study, has not yet begun recruiting, sponsored by Novo Nordisk A/S.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 300 participants
- Enrollment target
Study Summary
The study is testing UBT251 in participants with type 2 diabetes. The purpose of this clinical study is to find out if UBT251 is effective and safe for treating participants with type 2 diabetes. Participants will either get UBT251, UBT251 placebo, semaglutide, or semaglutide placebo. Which treatment participants get is decided by chance. UBT251 is the treatment being tested and is not yet available for doctors to prescribe, while semaglutide is a medicine used to treat type 2 diabetes that doctors can already prescribe.
Interventions
- DRUG Semaglutide
- DRUG UBT251
- DRUG UBT251 Placebo
- DRUG Semaglutide Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2026-06-22 |
| Est. Completion | 2027-11-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07668388
The ClinicalTrials.gov registry entry for NCT07668388 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Semaglutide is the first listed.
NCT07668388 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07668388 about?
NCT07668388 is a clinical study titled "A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes". The study is testing UBT251 in participants with type 2 diabetes. The purpose of this clinical study is to find out if UBT251 is effective and safe for treating participants with type 2 diabetes. Participants will either get UBT251, UBT251 placebo, semaglutide, or semaglutide placebo. Which treatmen...
What is the current status of trial NCT07668388?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 300 participants. The study started on 2026-06-22. Estimated completion is 2027-11-15.
What interventions are being tested in trial NCT07668388?
The interventions under investigation include: Semaglutide (DRUG), UBT251 (DRUG), UBT251 Placebo (DRUG), Semaglutide Placebo (DRUG).
Who is sponsoring clinical trial NCT07668388?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.